Photo Credit: Nemes Laszlo
The following is a summary of “Optimizing treatment sequencing in multiple myeloma: a novel model to predict survival outcomes,” published in the November 2024 issue of Hematology by Petrucci et al.
Patients with multiple myeloma (MM) often require multiple treatment regimens, with each line becoming more challenging. A novel model compares treatment sequences to optimize patient outcomes.
Researchers conducted a retrospective study to compare MM treatment sequences and optimize patient outcomes.
They compared treatment sequences and outcomes for adults with newly diagnosed transplant-eligible (TE) or transplant-ineligible (TIE) MM across four treatment lines (first line [FL] to fourth-line [4L]). Inputs were derived from patient-level data from clinical trials and indirect treatment comparisons, with a base case prediction based on clinical practice data from Italy.
The results showed that for FL TE, overall survival (OS) ranged from 11.80–18.10 years, and progression-free survival (PFS) ranged from 4.82–13.42 years for FL, 0.66–6.03 years for second-line (2L), 0.81–1.76 years for third-line (3L), and 0.69–0.72 years for 4L. For FL TIE, OS was greatest for FL daratumumab regimens, ranging from 5.95–10.61 years, and PFS was greatest for FL daratumumab regimens, ranging from 2.12–7.48 years for FL, 0.53–4.73 years for 2L, 0.63–1.17 years for 3L, and 0.42 years for 4L.
They concluded that using the most effective treatment in FL-optimized sequencing improved patient outcomes.
Source: tandfonline.com/doi/full/10.1080/16078454.2024.2432815#abstract
